In terms of implications for future research, for the optimization of LMWH therapy for preventing thromboembolic disease in hospitalized COVID-19 patients, monitoring the level of anti-factor Xa could be useful, especially in patients with severe or critical forms of the disease. This evidence concerns the gene F10 and Thromboembolism.